Skip to main content

ADVERTISEMENT

bivalirudin

Original Contribution
11/01/2021
Dr. Fu and colleagues evaluated MACE and hemorrhagic event rates for an antithrombotic regimen using bivalirudin or UFH during PCI in ACS patients.
Dr. Fu and colleagues evaluated MACE and hemorrhagic event rates for an antithrombotic regimen using bivalirudin or UFH during PCI in ACS patients.
Dr. Fu and colleagues evaluated...
11/01/2021
Journal of Invasive Cardiology
Original Contribution
09/01/2016
This survey was conducted to better understand current United States (US) practices in terms of preferences regarding the selection of antithrombotic therapy in STEMI-PPCI, particularly in light of recent clinical trials.
This survey was conducted to better understand current United States (US) practices in terms of preferences regarding the selection of antithrombotic therapy in STEMI-PPCI, particularly in light of recent clinical trials.
This survey was conducted to...
09/01/2016
Journal of Invasive Cardiology
Update
09/05/2008
Despite the sharp rise in peripheral vascular interventions (PVI), complication rates have continued to be significant and, in fact, limb loss has trended upwards.
Despite the sharp rise in peripheral vascular interventions (PVI), complication rates have continued to be significant and, in fact, limb loss has trended upwards.
Despite the sharp rise in...
09/05/2008
Vascular Disease Management
Original Research
09/05/2008
Unfractionated heparin is the current antithrombotic agent utilized during peripheral angioplasty procedures.
Unfractionated heparin is the current antithrombotic agent utilized during peripheral angioplasty procedures.
Unfractionated heparin is the...
09/05/2008
Vascular Disease Management
Case Report
09/05/2008
Advantages of various direct thrombin inhibitors, a modified dosing schedule for bivalrudin, and experience with monitoring parameters are described. These advantages may form the basis for consideration when alternative anticoagulation to...
Advantages of various direct thrombin inhibitors, a modified dosing schedule for bivalrudin, and experience with monitoring parameters are described. These advantages may form the basis for consideration when alternative anticoagulation to...
Advantages of various direct...
09/05/2008
Vascular Disease Management
Review
09/05/2008
Bivalirudin is a direct thrombin inhibitor with specific and reversible actions.It is a synthetic, 20-amino acid peptide with a molecular weight of 2180 daltons. Bivalirudin directly inhibits both circulating and bound thrombin by binding to...
Bivalirudin is a direct thrombin inhibitor with specific and reversible actions.It is a synthetic, 20-amino acid peptide with a molecular weight of 2180 daltons. Bivalirudin directly inhibits both circulating and bound thrombin by binding to...
Bivalirudin is a direct thrombin...
09/05/2008
Vascular Disease Management